# Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase

> **NCT02258607** · PHASE1 · TERMINATED · sponsor: **Sierra Oncology LLC - a GSK company** · enrollment: 21 (actual)

## Conditions studied

- Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Momelotinib (MMB)
- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT02258607
- **Lead sponsor:** Sierra Oncology LLC - a GSK company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-03-11
- **Primary completion:** 2016-07-19
- **Final completion:** 2017-02-27
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2019-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02258607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02258607, "Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02258607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*